Latest papers

Respiratory syncytial virus persistence in chronic obstructive pulmonary disease.

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.

Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.

Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology.

Infection of mice with respiratory syncytial virus during neonatal life primes for enhanced antibody and T cell responses on secondary challenge.

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

RSV 2007: recent advances in respiratory syncytial virus research.

Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic.

IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease.

Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.

Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.

Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.

Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection.

Virally delivered cytokines alter the immune response to future lung infections.

Bovine respiratory syncytial virus infection: immunopathogenic mechanisms.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.